Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Tyrosine kinase receptors Stories

2012-08-20 00:20:05

Tokyo, Aug 20, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received orphan drug designation from Japan's Ministry of Labour, Health and Welfare for its multikinase inhibitor lenvatinib mesylate ("lenvatinib") for the treatment of thyroid cancer, the drug's prospective indication.Lenvatinib, discovered and being developed in-house, is an anti-angiogenic agent with a unique inhibitory profile against the receptor tyrosine kinase family of kinases. It is a potent...

2012-06-22 16:08:18

Protein binds to growth factor receptor, priming it for normal function; Likely tie to 4 cancers Once considered merely a passive link between proteins that matter, Grb2 - pronounced "grab2" - actually lives up to its nickname with its controlling grip on an important cell signaling pathway, scientists at The University of Texas MD Anderson Cancer Center report in the June 22 issue of Cell. "Grb2 is a switch that controls normal signaling through the fibroblast growth factor receptor...

2012-06-04 04:24:11

(Ivanhoe Newswire) --Almost twelve million -- that´s how many cancer patients are living in the U.S. But what happens when the patients are no longer responsive to the drugs created to treat them? It´s a problem researchers at Case Western Reserve University are working to better understand. Researchers say overactive epidermal growth factor receptor (EGFR) signaling has been linked to the development of cancer. They found many patients have developed resistance to the drug...

2012-06-02 02:20:16

CHICAGO, June 2, 2012 /PRNewswire/ -- -- TLE3 Biomarker Over-expressed in HER2-positive, Hormone Receptor-positive, and Triple-negative Breast Cancers -- -- EGFR status May Facilitate Therapeutic Decision-making in Head and Neck Cancer -- Caris Life Sciences announced today the utility of the company's Caris Target Now(TM) evidence-based molecular profiling service in the characterization of breast and head and neck cancers. These data were presented today at the...

2012-05-17 09:26:40

Targeted therapies have been studied for years, but recent laboratory research is providing robust clues about drugs that might work better in combination, particularly in treating cancers that have become resistant to therapy. That kind of information is behind a novel clinical trial at Georgetown Lombardi Comprehensive Cancer Center that combines cetuximab and lapatinib. Findings from this phase I study will be presented at the American Society of Clinical Oncology annual meeting in...

2012-03-06 06:22:01

(Ivanhoe Newswire)-- Metastasis is the spread of breast cancer due to an original tumor; this process is the leading cause of death for women with breast cancer, but now there´s hope. Researchers led by Stefan Offermanns and Thomas Worzfeld, in Germany produced data in mice and humans that implies that the protein Plexin-B1 represents a new potential therapeutic target to treat patients with breast cancer found to overexpress the molecule ErbB-2. AN Estimated 30% of all breast...

2012-03-02 01:33:11

The main cause of death in women with breast cancer is spread of the original tumor to distant sites, a process known as metastasis. New therapeutic targets are urgently needed. A team of researchers led by Stefan Offermanns and Thomas Worzfeld, at the Max-Planck-Institute for Heart and Lung Research, Germany, has now generated data in mice and humans that suggest that the protein Plexin-B1 represents a new candidate therapeutic target to treat patients with breast cancer found to overexpress...

2012-02-13 23:03:47

Breast cancers expressing the protein HER2 have a particularly poor prognosis. Treatment with trastuzumab (Herceptin) benefits some patients with HER2-positive breast cancer, but it is not as effective as had been hoped. Researchers are therefore seeking ways to enhance the effectiveness of trastuzumab. In this context, a team of researchers led by Ronald Levy, at Stanford University, Stanford, has identified a sequential treatment regimen that enhances the effectivenss of trastuzumab in...

2012-02-07 09:55:31

Study may aid in development of improved therapies for glioblastoma A recent discovery by Van Andel Research Institute (VARI) scientists enables the prediction of patient sensitivity to proposed drug therapies for glioblastoma — the most common and most aggressive malignant brain tumor in humans. The study, published in January in the Proceedings of the National Academy of Science, investigated glioblastoma models characterized by cell signaling activation and gene amplification...

2012-02-06 22:28:20

Study may aid in development of improved therapies for glioblastoma A recent discovery by Van Andel Research Institute (VARI) scientists enables the prediction of patient sensitivity to proposed drug therapies for glioblastoma — the most common and most aggressive malignant brain tumor in humans. The study, published in January in the Proceedings of the National Academy of Science, investigated glioblastoma models characterized by cell signaling activation and gene amplification...